PCSK9 List Price Discounts Of 67% To 85% Suggested By ICER Analysis

Methods and conclusions for group’s report on the value and optimal pricing for Repatha and Praluent draw criticism from drug industry stakeholders, some policy experts. Approach includes cost-effectiveness review, novel US budget impact analysis.